IONS - Why Ionis Pharmaceuticals Stock Popped Today | Benzinga
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo.
What To Know: The topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome boosted Ionis stock on Tuesday. Furthermore, olezarsen demonstrated a favorable safety and tolerability profile. In preparation for the first possible ...